Common molecule arms itself to fight cancer, influenza

Researchers from the University of Warwick in the United Kingdom have developed a genetically engineered common molecule capable of being programmed to fight cancer, influenza and other diseases.

Led by Alfonso Jaramillo in the Warwick's school of life sciences, the research into programming ribonucleic acid (RNA) could provide personalized programmable defenses of the body. Alerting the gene expression of the RNA cells allow for instructions to be sent to the cell and tell them what to do. Similar to software on a computer or mobile applications, the "virtual machine" of the cell will be able to perform specific actions to treat a variety of diseases.

"The capabilities of RNA molecules to interact in a predictable manner, and with alternative conformations, has allowed us to engineer networks of molecular switches that could be made to process arbitrary orders encoded in RNA,” concluded Jaramillo. "Throughout the last year, my group has been developing methodologies to enable RNA sensing the environment, perform arithmetic computations and control gene expression without relying on proteins, which makes the system universal across all living kingdoms. The cells could read the RNA 'software' to perform the encoded tasks, which could make the cells detect abnormal states, infections, or trigger developmental programs."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.